Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
about
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysisRoutine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.Predictors of Treatment Failure in HIV-Positive Children Receiving Combination Antiretroviral Therapy: Cohort Data From Mozambique and Uganda.Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysisLong-term virological outcome in children on antiretroviral therapy in the UK and Ireland.First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapyBacks against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreakFirst-line antiretroviral drug discontinuations in childrenAbacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.Pediatric HIV infection: the state of antiretroviral therapy.Pharmacotherapy of pediatric and adolescent HIV infection24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.Treatment of HIV infection: Swedish recommendations 2009.Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use.Pediatric antiretroviral therapy.Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.The glory of guidelines and the twilight of reality: controversies and challenges in the prevention and treatment of HIV in children.Antiretroviral therapy in children: recent advances.Antiretroviral use in Italian children with perinatal HIV infection over a 14-year period.Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infectionWhen to start, what to start and other treatment controversies in pediatric HIV infection.
P2860
Q21999480-6F72F401-FE2A-4A8A-B5F4-A5648F51E5CCQ30539434-F2B31342-1C5F-41C6-ADCE-0E96EE54A195Q30997469-22867BE8-1546-433D-A4DE-8B7A924CF105Q33624953-B9A28AF1-5600-48DC-82F2-601C67127684Q34410947-70202D39-3B7E-4A82-9276-C97C7F651A59Q35034306-EFF96D83-E71B-4B23-B114-5E24C310AE1DQ35205900-990710C8-562B-4E28-B125-EFB2AC3CABD8Q35598919-4825F248-E653-4DF2-9BF6-866601898091Q36278763-9AFF37FF-9267-4288-89A7-B22134C9CCB2Q36501872-2B2F8738-FAFE-48DC-9F9E-7438C0ECB54EQ37029110-7965FE92-E36D-495D-99D0-6CFEB01BD1B9Q37124873-3906F278-73F6-43B6-A6EC-0DA7CBBD7F50Q37240305-63C2F11D-7B5E-4113-8DA5-6EFFF21B9FA8Q37299209-300F4E54-B490-4E1C-A7E9-AD0948CDDBB1Q37634509-D603C836-C8BB-473A-97F5-EF0791F107A6Q37638863-AC224043-74D2-40A7-80A2-5016E7D44237Q37816389-78B05D5D-E47E-4D63-9B92-06ACD6135C22Q37925813-863484CD-9079-44DB-AF26-89BCD68C9673Q38040150-C560074B-8832-42CB-922C-C37181125DDAQ38062862-04B350E0-0687-431E-BA64-D80FBEB2F14CQ38433613-DF8DCA6C-CF1C-4702-8E38-7FED3C0DFFE1Q41505058-83FEAB91-F6F2-4488-A5DF-6A7FCCE34463Q41886773-EDF12686-FB0C-47B5-9769-FF9A6633CF20Q44986291-E606E0FB-68B4-4493-B69C-D36D403A1A25
P2860
Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Lamivudine/abacavir maintains ...... ir beyond 5 years in children.
@en
Lamivudine/abacavir maintains ...... ir beyond 5 years in children.
@nl
type
label
Lamivudine/abacavir maintains ...... ir beyond 5 years in children.
@en
Lamivudine/abacavir maintains ...... ir beyond 5 years in children.
@nl
prefLabel
Lamivudine/abacavir maintains ...... ir beyond 5 years in children.
@en
Lamivudine/abacavir maintains ...... ir beyond 5 years in children.
@nl
P2093
P1433
P1476
Lamivudine/abacavir maintains ...... ir beyond 5 years in children.
@en
P2093
A Compagnucci
A S Walker
C Feiterna-Sperling
C Giaquinto
F Candeias
G Castelli-Gattinara
P304
P356
10.1097/QAD.0B013E3280E087E7
P407
P577
2007-05-01T00:00:00Z